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ABSTRACT
Recent evidence indicates that protein kinase CK1α may support the growth 
of multiple myeloma (MM) plasma cells. Here, by analyzing a large cohort of MM 
cases, we found that high CK1α mRNA levels are virtually associated with all MM 
patients. Moreover, we provided functional evidence that CK1α activity is essential for 
malignant plasma cell survival even in the protective niche generated by co-cultures 
with bone marrow stromal cells. We demonstrated that CK1α inactivation, while toxic 
for myeloma cells, is dispensable for the survival of healthy B lymphocytes and stromal 
cells. Disruption of CK1α function in myeloma cells resulted in decreased Mdm2, 
increased p53 and p21 and reduced expression of β-catenin and AKT. These effects 
were mediated partially by p53 and caspase activity. Finally, we discovered that 
CK1α inactivation enhanced the cytotoxic effect of both bortezomib and lenalidomide. 
Overall, our study supports a role for CK1α as a potential therapeutic target in MM in 
combination with proteasome inhibitors and/or immunomodulatory drugs.
INTRODUCTION
Multiple myeloma (MM), the second most frequent 
hematologic neoplasia accounting for about 10–15% of 
all blood tumors [1], is characterized by the progressive 
growth of malignant clonal plasma cells (PCs) in 
the bone marrow (BM) where they find a favourable 
microenvironmental niche. Often myeloma cells develop 
resistance to therapy, likely due to a continuous selection 
of more biologically aggressive subclones [2].
Among the several signalling pathways regulating 
MM cell growth, the Wnt/β-catenin and the PI3K/
AKT cascades are of particular importance for MM 
expansion. PCs from MM patients and human MM cell 
lines (HMCLs) express Frizzled receptors and LRP5/6 
co-receptors, as well as high levels of phosphorylated 
AKT on Ser473, which depends on mTOR activity [3]. 
Both β-catenin and AKT act as oncogenes and display 
an increased activity in a wide variety of malignant 
tumors, including MM [4, 5]. Moreover, BM stromal cells 
(BMSC) release Wnt or other growth factors which can 
potentially contribute to MM cell drug resistance [4, 6], 
triggering β-catenin and the PI3K/AKT signalling [7].
Protein kinase CK1 is a highly conserved family 
of monomeric serine/threonine kinases composed by 
seven members (α, β, γ1, γ2, γ3, δ, ε) which display 
the highest homology in their kinase domain (50–90% 
identical) with overlapping substrate specificity. CK1 
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members regulate membrane biology, molecule transport, 
signal transduction, transcription, translation and DNA-
damage response [8–10]. CK1α, which is encoded 
by the CSNK1A1 gene, mapping on chromosome 5 at 
5q32, regulates the Wnt/β-catenin signalling pathway. 
CK1α phosphorylates β-catenin at Ser45, priming it 
for the subsequent protein kinase GSK3-dependent 
phosphorylation at Ser33/37/Thr41, which tags the protein 
for proteasome-mediated degradation [11]. However, 
CK1α may also phosphorylate LRP6, triggering Wnt-
mediated intracellular signalling [12].
CK1α is also a regulator of the AKT pathway. It has 
been reported that in human embryonic kidney cells CK1α 
phosphorylates DEPTOR (an mTOR inhibitor), which is 
then targeted to the proteasome, thus activating mTOR-
mediated survival pathways [13, 14]. Since mTOR in turn 
regulates AKT activation [15], CK1α could indirectly 
modulate AKT function. 
CK1α also phosphorylates the tumor suppressor 
p53 [16] and stimulates the binding of murine double 
minute chromosome 2 (Mdm2) to p53, therefore 
inhibiting p53 function [17, 18]. In mouse models, CK1α 
loss of function in intestinal epithelial cells caused a 
strong activation of the Wnt pathway, however it did not 
lead to tumor formation as long as p53 function remained 
intact [19, 20]. On the opposite, in a murine acute 
leukemia (AML) model, CK1α loss of function resulted 
in a dramatic disadvantage for the leukemic clone growth, 
provided the presence of an intact p53 function [21]. 
Furthermore, the role of CK1α in mediating tumor cell 
survival is supported by the finding that treatment with 
the immunomodulatory drug (iMID) lenalidomide (Lena) 
induced the E3 ubiquitin ligase CUL4-RBX1-DDB1-
CRBN (CRL4CRBN)-mediated ubiquitination of CK1α in 
del(5q) myelodysplastic syndromes (MDS), in which one 
CSNK1A1 allele is lost, with degradation of the residual 
CK1α protein [22]. 
To inhibit CK1α activity, specific small ATP-
competitive molecules have been developed. D4476 
(4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-
1H-imidazol-2-yl]benzamide) is a cell-permeant inhibitor 
specific for CK1. It has been demonstrated that D4476 
does not inhibit other important kinases (like ERK2, JNK, 
MSK1, PDK1 and PKA) and it is the best CK1 inhibitor 
commercially available [23].
More recently, it has been demonstrated that CK1α 
also sustains MM cell survival [24]. Here, we investigated 
CSNK1A1 mRNA expression in a large microarray dataset 
of MM cases and analyzed CK1α  role in MM cell growth, 
also in BM microenvironment models. We found that 
CK1α inhibition/silencing causes cell cycle arrest and 
apoptosis of MM cells in a p53-Mdm2 dependent manner, 
overcoming BMSC-dependent protection. Mechanistically, 
CK1α inhibition caused downregulation of the β-catenin 
and AKT survival pathways and empowered the cytotoxic 
and cytostatic effect of bortezomib (BZ) and Lena. 
RESULTS 
CK1α expression and cellular localization is 
different between MM cells and normal cells
In most available gene expression profiling (GEP) 
datasets we found that CSNK1A1 mRNA is significantly 
overexpressed throughout the progression from normal 
to highly malignant PCs (Oncomine™) [25–27]. Also, 
CSNK1A1 mRNA was found overexpressed in XBP1s-
expressing transformed PCs from transgenic mice [28]. 
To further validate these data, we investigated GEP data 
of BM plasma cells obtained from 4 healthy controls, 
129 MM, 36 plasma cell leukemia (PCL) patients, 
and 18 MM cell lines. More than 90% of malignant 
plasma cells cases overexpressed CSNK1A1 mRNA 
compared to controls (Figure 1A). We next performed 
a correlation between CSNK1A1 mRNA expression 
and the different molecular groups included in the TC 
classification: TC1, characterized by the t(11;14) or 
t(6;14) with high expression of CCND1 or CCND3; 
TC2, characterized by absence of IGH translocation, 
low levels of CCND1 and hyperdiploid status; TC3, 
characterized by absence of IGH translocation and 
CCND2 expression; TC4, showing high level of 
CCND2 and the presence of t(4;14); TC5, expressing 
the highest level of CCND2 in association with 
MAF translocations [29, 30]. CSNK1A1 mRNA was 
significantly higher in TC2 samples compared to the 
other TC groups (Figure 1B). We have also evaluated 
the absolute transcript levels of CSNK1A1 in 17 
symptomatic MM and 2 primary PCL patients, included 
in GSE66293 proprietary dataset [31], investigated at 
diagnosis and first relapse. No significant difference 
in CSNK1A1 mRNA expression was observed 
between these two conditions (Figure 1C). To further 
corroborate the mRNA data, we next performed a 
survey of CK1α protein expression in purified CD138+ 
malignant PCs from MM patients and HMCLs showing 
high CK1α protein levels expression in all the samples 
analyzed (Figure 1D; Table 1A summarizes the clinical 
features of the MM patients investigated in this set of 
experiments). Densitometric analysis of CK1α protein 
expression confirmed that there is no difference between 
newly diagnosed and relapsed patients (Figure 1E).  
Previous studies reported that CK1α is detected 
in all cellular compartments and that its subcellular 
distribution is cell-cycle dependent [32]. We found 
that CK1α localized mainly in the cytoplasm of 
healthy B lymphocytes, while it was present both in the 
cytoplasm and in the nucleus of malignant PCs from 
MM and PCL patients and in all the HMCLs tested 
(Supplementary Figure 1). This different localization 
of CK1α was present also in a MM cell line, called 
SaMMi, which was generated in our laboratory from a 
primary tumor (see Table 2 for details). 
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CK1α inhibition causes MM cell apoptosis even 
in the presence of BMSCs
To confirm that high levels of CK1α kinase in MM 
are functionally relevant, we treated MM cells with the 
CK1 inhibitor D4476 at different concentrations for as 
long as 48 h. Annexin V/PI staining and FACS analysis 
showed that MM cells exposed to D4476 underwent 
a remarkable amount of apoptosis starting from the 
concentration of 10 µM for INA-6 (the most sensitive 
MM cell line) reaching 40 µM for H929 and U-266 (the 
least sensitive). SaMMi cells were also very responsive 
to D4476-induced apoptosis at a concentration as low 
as 5 µM. D4476 induced MM cell apoptosis both in 
IL-6/stroma dependent (INA-6, SaMMi, U-266) and 
independent (H929) HMCLs. Treatment with the vehicle 
alone (DMSO) did not cause a significant amount of 
apoptosis compared to untreated cells (Figure 2A). To test 
Figure 1: CK1α mRNA and protein expression in MM patients and cell lines. (A) CSNK1A1 mRNA expression analysis 
on 129 MM patients (pts) PCs (left panel), 36 PCL patients PCs (middle panel), 18 MM cell lines (right panel), compared to CSNK1A1 
mRNA expression level of 4 healthy controls PCs. All primary malignant PCs were purified from diagnostic BM aspirates. Samples were 
stratified according to CSNK1A1 mRNA expression as follow: normal (value = mean of controls ± 2SD), low (value < mean of controls - 
2SD) and high (value > mean of controls + 2SD). The HMCLs used were UTMC2, KMS12BM, LP1, INA-6, CMA-03, DELTA 47, H929, 
KMS11, OPM2, RPMI-8226, KMS34, MM.1.144, KMS20, KMS26, KMS18, U266, CMA-0306, MM1S, listed according to CSNK1A1 
expression, having UTMC2 the lowest and MM1S the highest expression. Among those, UTMC2 was the only one that had CSNK1A1 
mRNA expression level lower than controls. **** = p < 0.0001 according to the Chi square test for trend. (B) Box plot of CSNK1A1 
absolute expression level as detected by GEP in 4 healthy donors (N) and different MM TC groups: TC1 (34 pts), TC2 (30 pts), TC3 
(40 pts), TC4 (19 pts); TC5 (6 pts). p = 1.454 × 10-6 was calculated by Kruskal-Wallis test. (C) Box plot of CSNK1A1 absolute expression 
level as detected by GEP in 17 symptomatic MM and 2 primary PCL patients, included in GSE66293 proprietary dataset [31] investigated 
at diagnosis and first relapse. Patients were treated with BZ- based therapeutic regimens. No significant difference was observed between 
at diagnosis and relapsed samples (p = 0.212) using Wilcoxon signed-rank test. (D) WB analysis (upper panel) and the corresponding 
densitometry values of CK1α expression in 30 MM patient derived CD138+ PCs and in HMCLs INA-6, U-266, H929 and SaMMi. Grey 
bars represent newly diagnosed patients, white bars represent relapsed patients and black bars are cell lines. GAPDH or α-tubulin was used 
as a loading control. (E) Densitometric analysis of CK1α protein expression of MM patients described in D, grouped in new diagnosis and 
relapsed MM patients. Values are normalized over CK1α expression of INA-6 cell line. 
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the effects of D4476 in control cells, we treated PBMCs 
from healthy donors with D4476 at different doses for 48 h 
and analyzed apoptosis in the CD19+ fraction by flow 
cytometry. The CK1 inhibitor did not cause any significant 
changes in apoptosis of CD19+ healthy B lymphocytes at 
any concentration used compared to DMSO treated cells, 
indicating no toxicity for normal B cells (Figure 2B). 
Also D4476 treated CD138+ PCs isolated from seven 
MM patients underwent, on average, a significant amount 
of apoptosis compared to untreated cells (Figure 2C). 
When  CK1 inhibition was tested also in a model of 
protective microenvironment [33] we observed that 
BMSCs were not able to protect INA-6 or SaMMi MM 
cells from D4476-induced cell death (Figure 2D– 2E). 
To note, HS-5 stromal cells protected SaMMi from 
doxorubicin-induced apoptosis (Supplementary Figure 2) 
showing that also this new cell line is suitable for the BM 
microenvironment model experiments. CK1 blockade had 
cytotoxic consequences mainly on malignant PCs, since 
HS-5 cells were spared by D4476-induced cytotoxicity 
(data not shown). Most importantly, the apoptotic effect of 
D4476 was also found in patient-derived PCs co-cultured 
with HS-5 or patient-derived BMSCs (Figure 2F–2G; see 
Table 1B for clinical features of patients). To note, even 
though we observed higher protection by patient-derived 
BMSCs compared to the HS-5 stromal cell line, D4476 
was still able to induce MM cell apoptosis. These results 
suggest  a pro-survival role of CK1 for MM cells also in 
the BM microenvironment context. 
CK1 blockade associates with activation of a 
p53-dependent apoptotic cascade
D4476-induced apoptosis was accompanied by 
increased expression levels of pro-apoptotic proteins 
(Bax, Bak, cleaved PARP) and decreased expression 
of the pro-survival molecule Mcl1 (Supplementary 
Figure 3A). It was previously shown that CK1α promotes 
p53 degradation in different cell types [16, 17]. Indeed, 
also in INA-6, U-266, and SaMMi MM cells, D4476 
caused an increase of p53 protein levels with a consequent 
upregulation of its target p21 and a reduction of Mdm2 
protein (Supplementary Figure 3B). Altogether, these 
findings support the view that D4476-induced apoptosis 
could be mediated by the activation of a p53-dependent 
response.
CK1α silencing causes apoptosis and cell cycle 
arrest
To validate the results obtained with the chemical 
inhibition of CK1α, we used RNA interference (RNAi) to 
knockdown CK1α protein in INA-6 and H929 cells. As 
shown in Figure 3, CK1α knockdown (obtained both with 
electroporation of double strand (ds) siRNA or through the 
generation of IPTG inducible CSNK1A1 specific shRNAs–
see methods) determined a boost of apoptosis in INA-6 
cells grown alone (Figure 3A–3B), or in the presence of 
protective stromal HS-5 (Figure 3C). To check the effects 
of CK1α knockdown also in the BM microenvironment 
context, we pre-treated INA-6 clones with IPTG for 6 
days to induce the silencing of CK1α. Afterwards, control 
and silenced cells where co-cultured with HS-5 for 
additional 4 days (in the presence or absence of IPTG). 
CK1α knockdown determined an increase of apoptosis 
also in the context of the microenvironment, as shown by 
the increase in the amount of Annexin V positive cells, 
a raise of PARP cleavage and decrease of Mcl1 protein 
expression level (Figure 3C), therefore overcoming 
stromal cells protection. The apoptotic effect of CK1α 
silencing was observed also in H929 cells (Figure 3D–3E). 
In all samples, immunoblot analysis confirmed that 
CK1α was efficiently knocked down. Of note, IPTG 
treatment did not change CK1α expression levels and 
the apoptotic rate in wt INA-6 or H929 cells compared 
to untreated cells, confirming the efficacy/specificity of 
the silencing strategy (Figure 3B–3E). The pro-apoptotic 
effect of CK1α knockdown was further confirmed by cell 
cycle analysis. CK1α silencing determined an increase 
in the sub-G1 (apoptotic) phase and a reduction in G0/
G1 phase of the cell cycle (Supplementary Figure 4A), 
accompanied by a reduction of Mdm2 and an increase of 
p21, (Supplementary Figure 4B) confirming the activation 
of a p53-dependent cell cycle arrest.
Inhibition of CK1α leads to a caspase-dependent 
β-catenin and AKT degradation
Since β-catenin and AKT signalling pathways 
are crucial for MM pathobiology, and given the role of 
CK1α in modulating their activity in other cell types, 
we sought to investigate the role of CK1α on β-catenin 
and AKT transduction cascades in MM.  H929, INA-6 
and MM patient-derived plasma cells (grown alone or in 
co-culture with HS-5 or MM BMSCs) were treated with 
the indicated concentrations of D4476 and WB analysis 
was carried on. After CK1 inhibition, a reduction of 
phosphorylated β-catenin on Ser45 and on Ser33/37/Thr41 
and of phosphorylated AKT on Ser473 was observed in all 
the tested cells (Figure 4A–4C). However, unexpectedly, 
a reduction of total β-catenin and AKT protein levels was 
also observed, which could account for the lowering of 
the phosphorylated forms. RNAi of CK1α in two MM 
cell lines led to similar effects (Figure 4D–4E). To test 
if the observed reduction of β-catenin and AKT induced 
by CK1α inactivation was proteasome dependent, we 
treated H929 and INA-6 cells grown alone or in co-culture 
with HS-5 with D4476 for 48 h and with the proteasome 
inhibitor BZ for 18 h. D4476 prevented BZ-induced 
accumulation of β-catenin and AKT, indicating that the 
observed D4476-induced β-catenin and AKT decrease was 
not mediated by the proteasome (Figure 5A). 
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Table 1: Clinical and pathological features of MM patients analyzed
Sample Age Sex
DS 
Stage
ISS 
Stage
Paraprotein Type % PCs Karyotype New Diagnoses
Bone 
Disease
      (A)
MM 1 (SaMMi) 81 F IA III Micromolecular, λ 20 Abnormal karyotype; chr. 1 rearrangement; 
t(11;14)
Y N
MM 2 81 F IA III IgG/k 46 Normal Y N
MM 3 60 F IIA II IgG/k 80 Normal N Y
MM 4 77 F IIA I IgA/k 36.9 59% del(17p) Y Y
MM 5 74 M IA III IgG/k 63.8 del(13q) N N
MM 6 58 M IIIA I IgG/λ 20 Normal N Y
MM 7 72 M IIA I IgG/k 30 del(17p) Y Y
MM 8 58 M IIIA III IgA/k 16 Monosomy 13 (90%) Y Y
MM 9 71 F IIIA III IgG/k 19 Normal Y Y
MM 10 76 M IIA III IgG/k 45 IgH rearrangement N N
MM 11 74 M IIIA II IgG/λ 56 Trisomy 1q, 7, 13, 19, 22;
tetrasomy 15, del(8p), del(8p), t(2;3)
Y Y
MM 12 64 M IIIB III IgD/λ 80 Complex karyotype; t(11;14), t(1;14), 
del(13)
Y Y
MM 13 71 F IIA I IgG/λ 30 Partial del(1); partial 1q trisomy Y Y
MM 14 60 M IIIA I IgG/k 40.6 IgH rearrangement, del(13q) N Y
MM 15 68 F IA I IgG/λ 50 Normal N N
MM 16 60 F IA I IgA/λ 51.7 Complex karyotype; del(1p);presence of hyperdiploid clones N Y
MM 17 67 F IIIA III Non secretory 100 Monosomy 13 (76%) Y Y
MM 18 68 F IIIA III Micromolecular, k 80 Normal N Y
MM 19 69 M IIIA II Micromolecular, k 60 del(13q), MAF+, IgH-/+ Y Y
MM 20 71 M IIIA III IgG/λ 90.1 del(Y), del(13q) N Y
MM 21 81 M IIIA II Micromolecular, λ 35 NA Y Y
MM 22 76 F IIIA I IgG/k 95 Trisomy 5, 6, 9, 11, 15, 21 Y Y
MM 29 44 M IIIB III IgA/λ 24
Complex karyotype; Monosomy 13, 14, 
90% del(17p); Chr. 1 rearrangements, gain 
of 1q
N Y
MM30 76 M IA NA IgG/k 60 Normal karyotype, IgH rearr., trisomy 17 Y N
MM31 72 F IIIA III IgG/λ 100 Complex karyotype, hyperploid; del(13q) Y N
MM32 67 M IIIA II IgG/λ 100 NA Y Y
MM33 75 M IIIB III IgG/λ 40-100 Hypodiploid , t(14;16), del(13q), gain of 1q Y N
MM34 74 M IIIB III Micromolecular, λ 100 IgH-; del(17p), gain of 1q Y Y
MM35 56 M IIIA NA IgG/λ 100 NA N Y
MM36 42 F IIIA III IgA/k 90 Normal N Y
MM37 56 M IIIA I IgA/l 100
Complex karyotype (+1, del(1), dic(1;5), 
-13,-16, +17. FISH: del(1q), del(13q), del 
FGFR
N Y
MM38 70 M IIA II IgG/λ 20 NA N Y
MM39 74 M IIA II IgG/k 100 46XY; t(11;14); gain of 1q N Y
MM40 75 F IIIA II IgG/k 100 Complex karyotype; del(6p), del(17p), 
monosomy 10, 12, 13, 15, 16, 17
N Y
     (B)
MM 8 58 M IIIA III IgA/k 16 Monosomy 13 (90%) Y Y
MM 14 60 M IIIA I IgG/k 40.6 IgH rearrangement, del(13q) N Y
MM 23 59 M IIIA I IgG/k 44 Trisomy 1, 5, 9, 18, 19, 21 Y Y
MM 24 45 F IIIA III IgG/k 86 90% MAF-/+, Monosomy 13 N Y
MM 25 54 F IIA I IgG/k 22 t(4;14), Monosomy 13 N Y
MM 26 74 F IA I IgG/k 26.4 t(14;16) N Y
MM 27 76 F IIA III IgG/λ 22.8 Normal N Y
MM 28 75 M IIB III IgG/λ 14 36% del(Y), Monosomy 13 Y Y
MM plasma cells (A) and MM BMSC (B) were isolated from bone marrow of patients listed. Clinical staging was performed 
according to Durie-Salmon criteria and according to the International Staging System (ISS; albumin levels ≤ or > 35 g/L; 
β2-microglobulin levels ≤ or > 3.5 mg/L). All features are reported as data at diagnosis. M = Male, F = Female, DS = Durie-
Salmon, ISS = International Staging System, PC = Plasma Cell, Y = Yes/Present, N = No/Absent, NA = Not Available.
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Another AKT or β-catenin degradation mechanism 
could involve caspases and the tumor suppressor p53 [34, 35]. 
Previous studies in other cell types, showed a reduction of 
β-catenin upon increasing expression and activity of p53 
[35]. Moreover, other works described a caspase-dependent 
(mainly caspase 3, 6 and 8) and apoptosis-induced cleavage 
of β-catenin [36, 37]. Therefore, to test if this mechanism 
could be responsible of β-catenin and AKT degradation upon 
CK1α inhibition also in MM cells, we treated INA-6 cells 
with D4476 and the pan-caspase inhibitor Z-VAD-FMK. 
The addition of Z-VAD-FMK, prevented the D4476-induced 
reduction of β-catenin and AKT. The efficacy of the caspase 
inhibitor was confirmed by Annexin V/PI staining, Pro-caspase 
3 and Mcl1 protein detection by WB (Figure 5B). Next, we 
checked if other p53-inducing agents could correlate with 
a reduction in β-catenin expression in MM. Remarkably, 
doxorubicin determined an upregulation of the p53 axis (p53 
and p21 increase, reduction of Mdm2 protein level) with 
concomitant decrease in total β-catenin level in INA-6 and 
H929 (Figure 5C). Taken together, these results suggest that p53 
and caspase-mediated apoptosis could be responsible for the 
D4476-induced reduction of β-catenin and AKT in MM cells.
CK1 inhibition boosts bortezomib induced 
cytotoxicity
Since CK1α promotes MM cell survival, we 
sought to investigate if its inhibition could empower the 
cytotoxicity exerted by bortezomib. To this aim, we first 
assessed the extent of apoptosis of MM cells exposed in 
culture to D4476 and BZ. D4476 caused an increase of 
BZ-induced apoptosis in the BZ sensitive U-266, H929 
and INA-6 MM cells (Supplementary Figure 5A–5C). 
To evaluate the role of CK1α in BZ resistance, we also 
treated  RPMI-8226 (a less BZ sensitive cell line) with 
subtoxic doses of BZ (5 nM and 7.5 nM) in association 
with D4476. In this cell line, higher doses of BZ 
(10 nM) are needed to obtained BZ-induced cytotoxicity 
(Supplementary Figure 5D). CK1 inhibition in association 
with BZ was able to cause a moderately higher level of 
apoptosis compared to the single treatments and overcome 
BZ resistance in these cells. Furthermore, we have treated 
the UTMC2 cell line (which is reported to be BZ resistant 
[38]), with  D4476.  CK1 inactivation caused a strong 
dose dependent cytotoxicity in UTMC2 cells without 
an additive role with BZ. Moreover D4476 cooperated 
with BZ in inducing cell death also in the model of 
BM microenvironment of INA-6 grown in co-cultures 
with HS-5 or patient-derived BMSCs (Supplementary 
Figure 5F–5G). Importantly, CK1 inhibition was able 
to overcome patient BMSCs-induced resistance to 
BZ (Supplementary Figure 5G). To determine if the 
inhibition of CK1 and the proteasome could cause either 
an additive or a synergic effect in terms of cell growth 
arrest, we performed MTT assay evaluating cell viability 
after treating H929 cells with increasing concentration 
of BZ and D4476 and with the combination of the two 
compounds. The results showed that treatment of MM 
cells with BZ and the CK1 inhibitor was strongly synergic 
(Supplementary Figure 5H), as judged by the calculated 
Combination Index (CI) well below 1 (0.560). Moreover, 
we evaluated CK1α expression in MM patients with 
regards to BZ sensitivity, by analyzing CSNK1A1 mRNA 
expression in the public dataset GSE9782 [39]. Patients 
included in this study were treated with BZ and the dataset 
consisted of 169 patients evaluable for response. A slight 
significant difference was evidenced between 85 responder 
and 84 not responder MM patients, showing higher 
expression levels of CSNK1A1 in not responder patients 
(Supplementary Figure 5I).
CK1α is degraded by lenalidomide and its 
inhibition/silencing reinforces lenalidomide 
cytotoxicity 
To investigate if CK1α inhibition could modify 
iMIDs induced cytotoxicity, we first treated H929 
MM cells with different concentrations of Lena for 
4 and 7 days and we confirmed a pro-apoptotic and an 
antiproliferative/cytostatic effect of Lena in MM cells 
(Supplementary Figure 6). We next established that 
Lena causes a dose- and time-dependent degradation of 
CK1α protein in H929 with a subsequent reduction of its 
kinase activity (a decrease phosphorylation of its target 
phosphorylated Ser45 β-catenin was shown) (Figure 6A). 
A time-dependent Lena-induced degradation of CK1α 
Table 2: Immunophenotype and cytogenetic features of SaMMi MM cell line
Cell type CD138 CD38 CD117 CD19 CD56 CD45 Mono κ Mono λ
SaMMi + – – – + + - +
MM + +/– +/– – + + +/– +/–
SaMMi was compared with common MM cell lines (MM). Mono κ and Mono λ refer to clonal restriction for κ and λ light 
chain, respectively. The karyotype of SaMMi is the following:
45,X,-X,idic(1)(p11),der(1)t(1;3)(q25;q21),del(4)(q25),t(4;12)(q26;q13),
der(14)t(11;14)(q13;q32)t(8;14)(q23;q32),der(9)del(9)(p21)t(1;18;9)(q12;p11;q34)[25].ish idic(1)
(p11)(CDKN2C-,CKS1B++),der(1)t(1;3)(CDK2C+,CKS1B+)del(17)(p13.1p13.1)(TP53-,
17p11.1-q11.1+),der(18)t(1;18;9)(CKS1B+)[4].
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was confirmed also in U-266 and INA-6 cell lines at even 
earlier time points (4 h treatment) (Figure 6B, 6C). 
Next, Lena sensitive (H929, SaMMi) and insensitive 
(INA-6) cells were treated with Lena 10 µM for 3 or 
7 days. Forty-eight hours before harvesting, D4476 was 
added to the cell culture. D4476 strikingly cooperated with 
Lena in inducing MM cell death causing an increase of 
apoptotic cells compared to single treatments (Figure 7A). 
Interestingly, CK1α inhibition overcome Lena resistance 
in INA-6 cells. The therapeutic potential of Lena and 
D4476 was demonstrated also in models of myeloma BM 
microenvironment. Indeed, Lena potentiated the cytotoxic 
effect of D4476, overcoming BM protection also in 
SaMMi cells grown on HS-5 (Figure 7A, right panel). 
To test if the two drugs acts in a synergistic mode, 
we performed the MTT viability assay calculating the CI. 
H929 cells were treated with increasing doses of Lena or 
D4476 and with  the combination of the two compounds. 
The CI was 0.705 suggesting a synergy between the CK1 
inhibitor and Lena in reducing cell viability (Figure 7B). 
Next we evaluated the effect of D4476 and Lena 
on cell cycle. D4476 plus Lena caused a decrease in 
the percentage of cells in G1 and in S/G2M phases and 
an increase in the frequency of sub-G1 apoptotic cells, 
Figure 2: Effects of CK1 inhibition on MM cell survival. Quantification of apoptosis through Annexin V staining and FACS 
analysis in various models of MM cells treated with different concentrations of D4476 (ranging from 5 to 40 µM) for 48 h: (A) MM 
cell lines H929, U-266, INA-6, SaMMi; (B) average of 6 purified healthy B cells; (C) 7 independent CD138+ MM patient PCs (MM#11, 
MM#16, MM#8, MM#20, MM#21, MM#22, MM#29); (D) SaMMi cultured on HS-5 stromal cells (SaMMi/HS-5); (E) INA-6 cultured on 
HS-5 stromal cells (INA-6/HS-5) and on patient derived BMSCs (INA-6/MM patient BMSC); (F–G) patient derived CD138+ plasma cells 
cultured on HS-5 (MM patient PC/HS-5) or on MM patient derived BMSCs (MM patient PC/MM patient BMSC). Data represent the mean 
± SEM of 3-6 (A), six (B), seven (C), six (D) four-six (E), two (F) seven (G) independent experiments and are presented as arbitrary values 
over untreated cells. * indicates p < 0.05. DMSO 0.04% was also tested to exclude D4476 vehicle induced toxicity. 
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compared to the single treatments (Figure 7C). Also 
Ki-67 staining showed a significant reduction of active 
proliferating cells in the combined treatment (Figure 7C). 
Moreover, a raise of p21 and a decline of Mdm2 protein 
levels were stronger in the combination treatment 
compared to the single treatments (Figure 7D). 
Next, we treated CK1α-silenced (with siRNA 
against CSNK1A1) and control H929 cells with Lena 
10 µM for 3 days. The combination of Lena and CK1α 
silencing determined a stronger reduction of active 
proliferating cells as judged by a marked decline in the 
percentage of Ki-67 positive cells as compared to single 
treatments. An increase in apoptosis and the derangement 
in the cell cycle were also confirmed by a reduction in the 
uncleaved PARP, Mdm2 protein and a subsequent increase 
in p21. CK1α silencing empowered Lena induced CK1α 
protein degradation with subsequent further reduction in 
its activity on Ser45 β-catenin. Moreover, the combination 
of CK1α silencing and Lena also effectively decrease AKT 
phosphorylation and protein level (Figure 8).
DISCUSSION
In the present study we investigated the expression 
of CK1α in MM and provided evidence of its role in 
sustaining MM cell survival and proliferation. We also 
demonstrated that CK1α controls the levels of β-catenin 
and AKT, likely preventing their p53/caspase-mediated 
Figure 3: Effects of CK1 inhibition on MM cell survival. Quantification of apoptosis through Annexin V/PI staining and FACS 
analysis (upper panel) and determination of PARP cleavage and Mcl1 protein expression (lower panel) in INA-6 (A–C) or H929 (D, E) 
silenced for CK1α. CK1α silencing was obtained with electroporation of ds oligonucleotides directed against CK1α (A, D) or using IPTG 
inducible CK1α shRNA cellular clones (shRNA#1, shRNA#2, shRNA#3, B,C,E). Cells were treated with IPTG 500 µM (INA-6, and H929 
shRNA#1) or 1000 µM (H929 shRNA#3) for 7 days (INA-6 shRNA#1, and H929 shRNA#1 and 2) or 12 days (INA-6 shRNA#2). For the 
BM microenvironment model (C) INA-6 wt and shRNA#1 cells were treated with IPTG 500 µM for 6 days and subsequently plated on 
HS-5 stromal cells for an additional 4 days in the continuous presence of IPTG. In all experiments, IPTG was added also to wt INA-6 cells 
and H929 cells as control. GAPDH or α-tubulin was used as loading control. * indicates p < 0.05. Data represent the mean ± SEM of three 
independent experiments and are presented as arbitrary values over untreated cells.
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degradation cascade. We confirmed that CK1α is a target 
of Lena in MM cells and showed that its inactivation 
cooperates with BZ and Lena in inducing MM cell death, 
even in the protective niche of the BM microenvironment.
In a recent work, Hu et al. demonstrated that CK1α 
sustains MM cell survival [24]. However, no studies have 
investigated whether CK1α inactivation, especially in the 
MM BM microenvironment, could affect the cytotoxic 
effects of novel drugs, such as Lena, in the therapy of this 
hematological malignancy.
According to previous studies [24], we confirmed, 
in a larger and representative panel, that CSNK1A1 
mRNA is overexpressed in MM patients. Interestingly, 
we demonstrated for the first time a differential CSNK1A1 
mRNA expression between the TC groups. In particular, 
higher levels of CSNK1A1 were associated with TC2 
patients, who are characterized by the hyperdiploid 
status that involves several odd chromosomes including 
chromosome 5 where CSNK1A1 is located. Among the 30 
TC2 cases investigated, 26 (87%) showed extra copies of 
chromosome 5 (data not shown), thus suggesting that a 
gene dosage effect could be partially responsible of the 
high expression of the CSNK1A1 gene (Figure 1B).
To the best of our knowledge, this is the first report 
analyzing CK1α mRNA and protein expression in a large 
cohort of MM patients both at diagnosis and relapse. To 
note, we did not observe substantial differences between 
these two patient groups, suggesting that CK1α  levels 
could not correlate with the clonal evolution of MM 
plasma cells. We also demonstrated an atypical nuclear 
diffuse/microspeckled pattern localization in MM 
cells, pointing to a myeloma-specific function likely in 
Figure 4: Effects of CK1 inactivation on β-catenin and AKT signalling pathways. H929 (A), INA-6 grown alone or in co-
culture with HS-5 (INA-6/HS-5) (B), CD138+ patient derived PCs grown alone or on patient-derived BMSCs or HS-5 (C) were treated with 
D4476 40 µM (H929 and patient PCs) or 20 µM (INA-6) for 48 h and the expression of phosphorylated β-catenin on Ser45 (p β-catenin 
S45), phospho β-catenin on Ser33/37/Thr41 (p β-catenin S33/37/T41), phospho AKT on Ser473 (p AKT S473), total β-catenin and AKT 
was evaluated by WB. GAPDH or α-tubulin was used as loading control. In C: 1 = MM#11, 2=co-culture of MM#12 on BMSC obtained 
from MM#28; 3 = co-culture of MM#12 on BMSC obtained from MM#8; 4 = co-culture of MM#12 on HS-5; 5 = co-culture of MM#20 
on BMSC obtained from MM#28. The same analysis was performed in INA-6 (D, left panel) or H929 (E, left panel) cells electroporated 
with ds oligonucleotides against CK1α, in INA-6 wt or INA-6 CK1α shRNA#1 cellular clone treated with IPTG 500 µM for 1 week (D, 
middle and right panels) or in H929 wt, H929 CK1α shRNA#1 and shRNA#3 clones, treated with IPTG 500 µM (H929 wt and shRNA#1) 
or 1000 µM (shRNA#3) for 1 week (E, right panel).
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regulating gene transcription and/or chromatin DNA 
methabolism [13, 32].
The pro-apoptotic effects and alteration of cell 
cycle related to CK1α inactivation in MM cells support 
its pro-survival function in this malignancy. Both CK1α 
inhibition and silencing were able to overcome the BM 
microenvironment-dependent protection (Figures 2 and 3). 
By contrast, CK1α inhibition did not influence HS-5 
stromal cell or healthy B lymphocytes mortality, 
suggesting that this effect could be restricted to malignant 
MM cells.
Unexpectedly, we found that β-catenin levels decreased 
upon CK1α blockade. This was not prevented by proteasome 
inhibition, but it was rescued by caspase blockade. Similarly, 
CK1α inhibition or silencing was accompanied by AKT 
kinase decrease, in line with what expected according to the 
Figure 5: The D4476-dependent reduction of β-catenin and AKT is independent from the proteasome and is mediated 
by caspase and p53. (A) Expression of phospho β-catenin on Ser45 (p β-catenin S45), phospho β-catenin on Ser33/37/Thr41 (p β-catenin 
S33/37/T41), phosphorylated AKT on Ser473 (p AKT S473) and total β-catenin and AKT in H929 (left panel) and INA-6 cells, grown alone 
(middle panel) or in co-culture with HS-5 (INA-6/HS-5, right panel), treated with D4476 for 48 h and BZ for 18 h or the combination of the 
two compounds at the concentrations indicated in the Figure. (B) Expression of total β-catenin, AKT, Pro-caspase 3 and Mcl1 proteins in 
INA-6 cells treated with D4476 20 µM in association with Z-VAD-FMK for 48 h. In the combination treatment, cells were pretreated with 
Z-VAD-FMK 2 µM for 1 h before the addition of D4476. (C) INA-6 and H929 cells were treated with doxorubicin (Doxo) 1.2 µM for 18 h. 
β-catenin, p53, Mdm2, and p21 were evaluated by WB. In all experiments GAPDH was used as loading control.
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CK1α-mediated inhibition of the AKT inhibitor DEPTOR 
[14]. Similarly to what demonstrated in lymphoma cells 
[34], we provided evidence that, also in myeloma cells 
undergoing p53-dependent apoptosis, AKT is downregulated 
by a caspase-dependent mechanism. 
Moreover, it is known that both AKT [40, 41] and 
CK1α [18] can  phosphorylate and activate Mdm2 with 
the consequent degradation of p53.  In addition,  AKT 
decreases caspase 9 activity by phosphorylation on 
Ser196 [42],  thus promoting cell survival. A reduction 
in AKT protein level could therefore downmodulate 
Mdm2 phosphorylation with the subsequent p53 and 
caspase activation, in a positive feedback loop. The final 
effect would be the arrest of cell cycle and activation 
of apoptosis. Since MM cells rely on both β-catenin 
and AKT, their downregulation achieved with CK1α 
inactivation could be therapeutically relevant. To this 
regard, the reduction of BZ-induced AKT and β-catenin 
accumulation (a possible drawback of BZ) achieved upon 
CK1α inhibition may potentially overcome BZ resistance 
(Figure 5). Indeed,  CK1α inhibition synergically 
potentiated BZ toxicity in MM (Supplementary Figure 5). 
To note CSNK1A1 mRNA expression is higher in BZ 
resistant patients, suggesting the possibility that this kinase 
might influence the sensitivity to BZ. Importantly, CK1α 
inactivation reduced β-catenin and AKT proteins also in 
the presence of Lena, and effectively cooperates with this 
drug in inducing apoptosis and growth arrest, also in the 
BM microenvironment.
Taken together, our data support an oncogenic 
role of CK1α in MM, likely by impinging on critical 
microenvironment dependent survival pathways 
(Wnt/β-catenin and PI3K/AKT). Therefore, it would 
be worth pursuing to consider the design of novel 
selective CK1α inhibitors to be used in the clinical 
setting in association with conventional or novel anti-
myeloma agents.
MATERIALS AND METHODS
Patients and cell cultures
PBMC, MM and HS-5 cell lines, primary BMSCs from 
patients were isolated and cultured as previously described 
[31, 33, 43]. Malignant CD138+ PCs and healthy B cells were 
isolated with EasySep™ kits (STEMCELL Technologies, 
USA), after achieving informed consent according to the 
declaration of Helsinki. The internal Institutional Board 
approved the use of human material. SaMMi cell line was 
obtained from a 81 year old woman with a 20% PCs in the 
bone marrow. CD138+ SaMMi PCs were cultured in DMEM 
20% FBS with the addition of IL-6 2.5 ng/ml. Co-cultures of 
HS-5 or BMSCs with INA-6 or patient derived CD138+ PCs 
were stabilized as described in [33].The clinical features of 
the patients analyzed and the immunophenotype/karyotype 
of SaMMi are detailed in Tables 1 and 2.
GEP and data analysis
The study was performed in a cohort of 165 patients, 
representative of all the major forms of plasma cell dyscrasia. 
This dataset, publicly available at the NCBI Gene Expression 
Figure 6: Lenalidomide determines CK1α protein reduction in a dose and time dependent manner. (A) H929 cells were 
treated with Lena at different concentrations (1, 5, 10 µM) for 7 days (left panel) or with Lena 10 µM for 4 (4d) and 7 days (7d). U-266 (B) 
and INA-6 (C) were treated with Lena 10 µM for 4 h, 24 h and 72 h. CK1α, phosphorylated β-catenin on Ser45 (p β-catenin S45) and total 
β-catenin were evaluated by WB. GAPDH was used as loading control.
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Omnibus repository (accession #GSE66293), includes 4 normal 
controls (Voden, Medical Instruments, Italy), 129 MM, 24 
primary PCL (pPCL), 12 secondary PCL (sPCL) patients and 18 
HMCLs [31]. With the exception of sPCL, the cohort consists of 
newly diagnosed patients. PCs were purified from BM samples 
using CD138 immunomagnetic microbeads (MidiMACS 
system, Miltenyi Biotec, CA, USA). Samples were characterized 
for the presence of the most frequent chromosomal translocations 
and the ploidy status based on fluorescence in situ hybridization 
(FISH) evaluation criteria [44]: 48 showed an HD status; 34 
were characterized by the t(11;14) or t(6;14) translocations; 
19 had the t(4;14) translocation; 6 had either the t(14;16) or 
t(14;20) translocations; and 22 did not fall into any of the other 
groups. Details regarding the source of all HMCLs have been 
previously reported [31, 45, 46] and recently authenticated 
by STR profiling and/or gene mutational analyses. For gene 
expression analysis, samples were profiled on the GeneChip 
Human Gene 1.0 ST array (Affymetrix, CA, USA) as described 
[47]. The raw intensity expression values were processed by 
Robust Multi-array Average procedure (RMA) [48] with the re-
annotated Chip Definition Files from BrainArray libraries version 
19.0.0, available at http://brainarray.mbni.med.umich.edu. 
Cytokines and chemicals
IL-6 and IPTG were from Sigma-Aldrich (Italy); 
BZ and Lena from Selleck chemicals (USA); D4476 
(4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-
1H-imidazol-2-yl]benzamide) from abcam (UK); Z-VAD-
FMK from Enzo Life Science (UK).
Evaluation of growth and apoptosis
Apoptosis was assessed by Annexin V/Propidium 
Iodide (PI) staining (IMMUNOSTEP, Spain) [43]. FACS 
analysis was performed using a FACSCanto™Cell 
Cytometer and the FACSDiva™ software (Becton-
Dickinson, Italy).
Figure 7: Lenalidomide empowers D4476-induced apoptosis and cell cycle arrest. MM cells were treated with Lena for 
3 days (SaMMi, INA-6) or 7 days (H929), with D4476 for the last 48 h and with the combination of the two compounds at the doses 
indicated in the Figure. (A) Annexin V/PI staining and FACS analysis of the Lena sensitive cell lines, H929, SaMMi grown alone, or in 
co-culture with HS-5 (SaMMi/HS-5) and of the Lena resistant INA-6. (B) Synergistic effect of D4476 and Lena in reducing cell viability. 
Upper graph: dose response curve of H929 incubated for 72 hours with increasing concentrations of D4476 (grey squared curve). Lower 
graph: dose-response curve of cells incubated for 1 week with increasing concentrations of Lena alone (white round curve) or Lena plus 
D4476 (black triangle curve). In the combination treatment, D4476 was added for the last 72 h. Cell viability was assessed with MTT test 
and reported as percentage over DMSO treated cells. IC50 for D4476  was 60 µM and for Lena 10 µM. The CI between D4476 and Lena 
was calculated as to be 0.705. (C) Cell cycle analysis with Ki-67/PI staining (left panel) and total Ki-67 (right panel) in H929 and SaMMi 
cells. * indicates p < 0.05; # indicates p < 0.05 between samples treated with D4476 together with Lena and cells treated only with D4476. 
Data represent the mean ± SEM of three independent experiments. (D) Expression analysis of p21, Mdm2 and CK1α in H929 and SaMMi. 
GAPDH was used as loading control. 
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Assessment of drug concentration-effect and 
calculation of the combination index (CI)
H929 cells were plated in triplicate into 96 well plates in 
100 μl media. D4476, BZ and lenalidomide was added for 72 
h (D4476 and BZ) or 1 week (Lena) alone or in combination. 
Cell viability was analyzed with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT). Cells were washed 
by centrifugation, resuspended in 100 μl of growing media 
containing 0.25 mg/ml MTT and left in the incubator for 
2–3 h. Formazan blue precipitates were dissolved in DMSO 
and absorbance was read at 560 nm. CI was calculated as 
described  in [43].
Cell cycle analysis
5 × 105 cells were fixed in ice cold ethanol 70% v/v 
in PBS for 1 h. After washing in PBS (2 times), samples 
were stained with PI (50 µg/ml) and RNaseA 0.2 mg/ml 
(Sigma-Aldrich, Italy) for 30 min. Ki-67/PI staining was 
performed using FITC- or PE-conjugated Ki-67 (BD 
Pharmingen, Italy). FACS analysis was performed as 
above. 
Immunofluorescence
It was performed as in [43] with the following 
antibodies: anti-CK1α (abcam, UK), secondary Alexa-
Fluor 594-conjugated goat anti-rabbit (Life technologies, 
Italy). Specimens were mounted in Vectashield medium 
with DAPI (Vector Laboratories, USA) and analyzed using 
Leica TCS SP5 confocal microscope, oil objective 63x 
with the LAS Advances Fluorescence Leica Application 
Suite software (Italy).
Western blot (WB)
WB was performed as described [49]. Antibodies 
used were the following: CK1α, PARP, Mcl1, Ser45 
β-catenin, Ser33/37/Thr41 β-catenin, total β-catenin, 
Ser473 AKT, total AKT (Cell signaling Technology, MA, 
USA); Mdm2 (Millipore, Italy), GAPDH (Ambion, USA); 
Figure 8: Lenalidomide cooperates with CK1α silencing in inducing apoptosis and cell cycle arrest, modulating 
β-catenin and AKT survival signalling. Ki-67 positive H929 cells after transfection with CK1α siRNAs and siGLO green indicator 
and treated for 3 days with Lena (average of five independent experiments). * indicates p < 0.05. # indicates p < 0.05 between samples treated 
with Lena alone or in combination of CK1α silencing. Data represent the mean ± SEM of five independent experiments. The right panel 
shows a representative Contour Plot. Bottom panel: expression of phosphorylated β-catenin on Ser45 (p β-catenin S45), phosphorylated 
AKT on Ser473 (p AKT S473), total β-catenin and AKT. GAPDH was used as loading control.
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α-tubulin (Sigma-Aldrich, Italy); Bak (Merck, MA, USA); 
Bax, p21, p53 (Becton Dickinson, Italy); Caspase 3 (Enzo 
Life Science, UK). Images were acquired using the Image 
Quant LAS 500 chemiluminescence detection system (GE 
Healthcare,  USA).  Densitometric analysis was performed 
with Quantity One software (Bio-Rad, Italy).
mRNA silencing
RNAi was performed with nucleofection of ds 
siRNA and by the generation of inducible shRNA cell lines. 
Nucleofection
Electroporation of INA-6 and H929 was performed 
as described in [50] with siGLO Green scrambled 
siRNAs and CK1α targeting siRNAs ON-TARGETplus 
SMARTpool siRNA (Thermo Scientific, USA). CK1α 
target sequences were: GCGAUGUACUUAAACUAUU; 
GGAAUCAUUAGGAUAUGUU; AGAGUAACAUGA 
AAGGUUU; GGCUAAAGGCUGCAACAAA. Cells 
were harvested at 72 h after nucleofection.
shRNA lentiviral transduction
INA-6 and H929 were transduced with the IPTG 
inducible lentiviral particles carrying CSNK1A1-
specific shRNA (pLKO_IPTG_3XLacO, Sigma-
Aldrich, Italy). Three independent shRNAs sequences 
were chosen (TRCN0000006044, named shRNA#1, 
TRCN0000006287, named shRNA#2, TRCN0000006042, 
named shRNA#3). 2 × 104 cells were infected with 
a multiplicity of infection of 5, using the spinfection 
method (centrifuged at 1000 g for 45 min at 32°C) in the 
presence of 8 μg/ml polybrene (Sigma-Aldrich, Italy). 
Puromycin selection (0.5 µg/ml) was initiated two days 
after transduction. Once a cellular clone was established, 
to induce CK1α silencing, cells were incubated with 
500/1000 µM IPTG every two/three days for a total of 
one (in the case of shRNA#1 and shRNA#3) or two (in the 
case of shRNA#2) weeks, time lapse in which we obtained 
the best results in terms of CK1α knockdown efficacy.
Statistical analysis
Data obtained were evaluated for their statistical 
significance with the two-tail paired Student’s t test or 
ANOVA analysis of variance with post-hoc corrections, 
with the Chi square test for trend. Conventional statistical 
procedures were applied using standard packages of the R 
software. Values were considered statistically significant at 
p values below 0.05.
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